The FDA on November 16, 2023, approved KEYTRUDA® (Pembrolizumab) with Fluoropyrimidine and Platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative Gastric or GastroEsophageal Junction (GEJ) adenocarcinoma. KEYTRUDA® is a product of Merck & Co., Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
